SCHEMBL19951335

SCHEMBL19951335

Cc1ccccc1-c1nc(NC2CCC(C(=O)O)CC2)ccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 1/20 0.42
VCP P55072 2/20 0.40
CYP1A2 P05177 2/20 0.39
CYP3A4 P08684 2/20 0.39
CYP2D6 P10635 2/20 0.39
TSHR P16473 2/20 0.39
CLK4 Q9HAZ1 2/20 0.39
MEN1 O00255 1/20 0.39
CYP2C19 P33261 1/20 0.39
KMT2A Q03164 1/20 0.39
HSD17B10 Q99714 1/20 0.39
EPHX2 P34913 3/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPK1 P28482 1/20 0.38
HSD11B1 P28845 1/20 0.38
RORC P51449 3/20 0.38
ABL1 P00519 1/20 0.36
MALT1 Q9UDY8 1/20 0.36
NUDT1 P36639 1/20 0.35
CCR6 P51684 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23770784 0.89 SYK (0.38) SYKVCPCYP1A2CYP3A4CYP2D6
SCHEMBL19951403 0.89 MAPK3 (0.44) VCPTSHREPHX2IL1B
SCHEMBL29464468 0.89 SYK (0.38) SYKVCPCYP1A2CYP3A4CYP2D6
SCHEMBL19951375 0.89 SYK (0.38) SYKVCPCYP1A2CYP3A4CYP2D6
SCHEMBL19925161 0.89 SYK (0.38) SYKVCPCYP1A2CYP3A4CYP2D6
SCHEMBL19970087 0.85 CCNT1 (0.35) SYKVCPCYP1A2CYP3A4CYP2D6
SCHEMBL29464388 0.84 CCNT1 (0.34) SYKVCPEPHX2ALDH1A1HSD11B1
SCHEMBL19925074 0.84 CCNT1 (0.34) SYKVCPEPHX2ALDH1A1HSD11B1
SCHEMBL19925771 0.80 SCN1A (0.33) SYKHSD17B10ALDH1A1HSD11B1RORC
SCHEMBL19925214 0.80 SCN1A (0.33) SYKHSD17B10ALDH1A1HSD11B1RORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease NOVARTIS AG (CH) 2019-10-22 US disclosed
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 SYK 689/4885VCP 2880/4885CYP1A2 876/4885
US-10450273-B2 N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease CFTR, P2RY1, P2RX5 SYK 689/4885VCP 2880/4885CYP1A2 876/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.